These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2254493)

  • 21. [Means of increasing the therapeutic efficacy of corticosteroid ointments].
    Shekrota GS
    Vestn Dermatol Venerol; 1968 Mar; 42(3):65-6. PubMed ID: 5741249
    [No Abstract]   [Full Text] [Related]  

  • 22. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability of proprietary corticosteroid containing ointments.
    Trikam DS; Morton DJ
    Cent Afr J Med; 1985 Mar; 31(3):57-8. PubMed ID: 4016908
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-inflammatory activity of ointments of indomethacin and its calcium salt applied to abdominal skin of rat.
    Ogiso T; Ito Y; Iwaki M; Atago H
    Chem Pharm Bull (Tokyo); 1988 Feb; 36(2):757-62. PubMed ID: 3409382
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of rosacea with corticosteroid ointments].
    Samtsov AV
    Vestn Dermatol Venerol; 1976 Feb; (2):70-3. PubMed ID: 132811
    [No Abstract]   [Full Text] [Related]  

  • 26. Factors influencing the formulation of semisolid preparations with special reference to corticosteroid products.
    Worthington HE
    Acta Derm Venereol Suppl (Stockh); 1973; 53():29-34. PubMed ID: 4518660
    [No Abstract]   [Full Text] [Related]  

  • 27. [Skin dystrophy after prolonged application of corticosteroid ointments (experimental study)].
    Akimochkina RG; Kalugin VV
    Vestn Dermatol Venerol; 1969 Aug; 43(8):43-6. PubMed ID: 5399011
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug information: glucocorticoid-containing agents. Therapeutic main group: Steroid ointments. 3].
    Lumholtz IB
    Sygeplejersken; 1979 Nov; 79(44):15. PubMed ID: 260436
    [No Abstract]   [Full Text] [Related]  

  • 29. [Reducing the dosage by new technology].
    Steinhorst M
    Hautarzt; 2001 Jan; 52(1):p following 90 (91). PubMed ID: 11220248
    [No Abstract]   [Full Text] [Related]  

  • 30. Extensive striae distensae as a result of topical corticosteroid therapy in psoriasis vulgaris.
    Rogalski C; Haustein UF; Glander HJ; Paasch U
    Acta Derm Venereol; 2003; 83(1):54-5. PubMed ID: 12636026
    [No Abstract]   [Full Text] [Related]  

  • 31. [Epidermal reaction against hydrocortisone in different ointment bases (author's transl)].
    Wohlrab W; Zaumseil RP
    Dermatol Monatsschr; 1982 Apr; 168(4):236-42. PubMed ID: 7106335
    [No Abstract]   [Full Text] [Related]  

  • 32. [Drug information: therapeutic main group. Glucocorticoid-containing drugs: steroid ointments].
    Lumholtz IB
    Sygeplejersken; 1979 Oct; 79(40):21. PubMed ID: 260416
    [No Abstract]   [Full Text] [Related]  

  • 33. [Drug information: glucocorticoid-containing drugs. Therapeutic main group: steroid ointments].
    Lumholtz IB
    Sygeplejersken; 1979 Oct; 79(42):27. PubMed ID: 260426
    [No Abstract]   [Full Text] [Related]  

  • 34. Basics of compounding: tips and hints, Part 3: compounding with ointments, creams, pastes, gels, and gel-creams.
    Allen LV
    Int J Pharm Compd; 2014; 18(3):228-30. PubMed ID: 25306771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug information: glucocorticoid-containing drugs. Therapeutic main group: steroid ointments. 5].
    Lumholtz IB
    Sygeplejersken; 1979 Dec; 79(48):13. PubMed ID: 260465
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of hyperkeratotic dermatitis of the palms. Sequential treatment with a keratolytic gel and corticosteroid ointment.
    Baden HP
    Arch Dermatol; 1974 Nov; 110(5):737-8. PubMed ID: 4424786
    [No Abstract]   [Full Text] [Related]  

  • 37. Topical product design and extemporaneous compounding in dermatology.
    Krochmal L; Patel B
    Adv Dermatol; 1992; 7():231-52; discussion 253. PubMed ID: 1739582
    [No Abstract]   [Full Text] [Related]  

  • 38. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations.
    Gilbertson EO; Spellman MC; Piacquadio DJ; Mulford MI
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 2):318-21. PubMed ID: 9486706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations.
    Gibson JR; Kirsch J; Darley CR; Burke CA
    Clin Exp Dermatol; 1983 Sep; 8(5):489-93. PubMed ID: 6641007
    [No Abstract]   [Full Text] [Related]  

  • 40. Various vagaries of vasoconstriction.
    Burdick KH
    Arch Dermatol; 1974 Aug; 110(2):238-42. PubMed ID: 4855376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.